Literature DB >> 10754379

Comparison of the effects of acetylsalicylic acid, ticlopidine and cilostazol on primary hemostasis using a quantitative bleeding time test apparatus.

Y Tamai1, H Takami, R Nakahata, F Ono, A Munakata.   

Abstract

We examined and compared the effects of aspirin (ASA), ticlopidine (TP) and cilostazol (CS) on bleeding time (BT) in 10 healthy adult male subjects using a newly developed quantitative bleeding time (QBT) test apparatus capable of simultaneously measuring total blood loss (Tv), maximum bleeding rate (Rmax), and bleeding pattern in addition to BT. All 3 drugs inhibited platelet aggregation response to ADP, collagen, epinephrine and arachidonic acid (p < 0.05), but not to ristocetin. Following oral administration of ASA (330 mg/day) or TP (300 mg/day) for 3 days, BT was significantly prolonged (mean BT increased from 359.3 to 646.0 s, p < 0.001, and from 323.3 to 528. 7 s, p < 0.01, respectively) and Tv was significantly increased (from 14.5 to 30.2 microl, p < 0.05, and from 12.5 to 19.2 microl, p < 0.01, respectively). Aspirin also increased Rmax (from 0.118 to 0. 159 microl/s, p < 0.05). The prolonged bleeding patterns after administration of ASA and TP were both type III, which has been reported to be less likely to lead to bleeding accidents. In contrast, none of these QBT parameters were altered by CS administration. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10754379     DOI: 10.1159/000022512

Source DB:  PubMed          Journal:  Haemostasis        ISSN: 0301-0147


  11 in total

1.  The effect of Ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of cilostazol and its active metabolites in healthy Korean subjects.

Authors:  Ho-Sook Kim; Ga-Young Kim; Chang-Woo Yeo; Minkyung Oh; Jong-Lyul Ghim; Ji-Hong Shon; Eun-Young Kim; Dong-Hyun Kim; Jae-Gook Shin
Journal:  Br J Clin Pharmacol       Date:  2014-05       Impact factor: 4.335

2.  Antiplatelet Effect of Sequential Administration of Cilostazol in Patients with Acetylsalycilic Acid Resistance.

Authors:  Muzaffer Cakmak; Bora Demircelik; Mustafa Cetin; Zehra Cetin; Serhat Isık; Hulya Cıcekcıoglu; Feridun Vasfi Ulusoy; Beyhan Eryonucu
Journal:  Acta Cardiol Sin       Date:  2016-05       Impact factor: 2.672

Review 3.  Risks and benefits of triple oral anti-thrombotic therapies after acute coronary syndromes and percutaneous coronary intervention.

Authors:  Joakim Alfredsson; Matthew T Roe
Journal:  Drug Saf       Date:  2015-05       Impact factor: 5.606

4.  Study for determination of the optimal cessation period of therapy with anti-platelet agents prior to invasive endoscopic procedures.

Authors:  Tomoko Komatsu; Yoshiko Tamai; Hideki Takami; Kazufumi Yamagata; Shinsaku Fukuda; Akihiro Munakata
Journal:  J Gastroenterol       Date:  2005-07       Impact factor: 7.527

5.  A prospective, multicenter survey on the validity of shorter periendoscopic cessation of antithrombotic agents in Japan.

Authors:  Katsuhiro Mabe; Mototsugu Kato; Koji Oba; Soichi Nakagawa; Hideyuki Seki; Shinichi Katsuki; Kentaro Yamashita; Shoko Ono; Yuichi Shimizu; Naoya Sakamoto
Journal:  J Gastroenterol       Date:  2016-04-16       Impact factor: 7.527

Review 6.  PDE3 Inhibitors Repurposed as Treatments for Age-Related Cognitive Impairment.

Authors:  Shuichi Yanai; Shogo Endo
Journal:  Mol Neurobiol       Date:  2018-10-11       Impact factor: 5.590

Review 7.  Anti-platelet therapy: phosphodiesterase inhibitors.

Authors:  Paolo Gresele; Stefania Momi; Emanuela Falcinelli
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

Review 8.  The vascular effects of cilostazol.

Authors:  William S Weintraub
Journal:  Can J Cardiol       Date:  2006-02       Impact factor: 5.223

9.  Hemorrhagic cholecystitis in an elderly patient taking aspirin and cilostazol.

Authors:  David S Morris; John R Porterfield; Mark D Sawyer
Journal:  Case Rep Gastroenterol       Date:  2008-06-23

Review 10.  Safety and efficacy of cilostazol in the management of intermittent claudication.

Authors:  Yung-Wei Chi; Carl J Lavie; Richard V Milani; Christopher J White
Journal:  Vasc Health Risk Manag       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.